BACKGROUND: Low skeletal muscle radiodensity (SMD) is related to higher mortality in several cancers, but the association with colorectal cancer (CRC) prognosis is unclear. METHODS: This observational study included 3262 men and women from the Kaiser Permanente Northern California population diagnosed between 2006 and 2011 with AJCC stages I to III CRC. The authors evaluated hazard ratios (HRs) of low SMD for all-cause and CRC-specific mortality, assessed by computed tomography using optimal stratification, compared with patients with normal SMD. They also evaluated the cross-classification of categories of low versus normal SMD and muscle mass (MM) with outcomes. RESULTS: The median follow-up was 6.9 years. Optimal stratification cutpoints for SMD were 32.5 in women and 35.5 in men. In multivariate-adjusted analyses, among patients with CRC, those with low SMD demonstrated higher overall (HR, 1.61; 95% confidence interval [95% CI], 1.36-1.90) and CRC-specific (HR, 1.74; 95% CI, 1.38-2.21) mortality when compared with those with normal SMD levels. Patients with low SMD and low MM (ie, sarcopenia) were found to have the highest overall (HR, 2.02; 95% CI, 1.65-2.47) and CRC-specific (HR, 2.54; 95% CI, 1.91-3.37) mortality rates. CONCLUSIONS: In patients with CRC, those with low SMD were found to have elevated risks of disease-specific and overall mortality, independent of MM or adiposity. Clinical practice should incorporate body composition measures into the evaluation of the health status of patients with CRC. Cancer 2018;124:3008-15.
BACKGROUND: Low skeletal muscle radiodensity (SMD) is related to higher mortality in several cancers, but the association with colorectal cancer (CRC) prognosis is unclear. METHODS: This observational study included 3262 men and women from the Kaiser Permanente Northern California population diagnosed between 2006 and 2011 with AJCC stages I to III CRC. The authors evaluated hazard ratios (HRs) of low SMD for all-cause and CRC-specific mortality, assessed by computed tomography using optimal stratification, compared with patients with normal SMD. They also evaluated the cross-classification of categories of low versus normal SMD and muscle mass (MM) with outcomes. RESULTS: The median follow-up was 6.9 years. Optimal stratification cutpoints for SMD were 32.5 in women and 35.5 in men. In multivariate-adjusted analyses, among patients with CRC, those with low SMD demonstrated higher overall (HR, 1.61; 95% confidence interval [95% CI], 1.36-1.90) and CRC-specific (HR, 1.74; 95% CI, 1.38-2.21) mortality when compared with those with normal SMD levels. Patients with low SMD and low MM (ie, sarcopenia) were found to have the highest overall (HR, 2.02; 95% CI, 1.65-2.47) and CRC-specific (HR, 2.54; 95% CI, 1.91-3.37) mortality rates. CONCLUSIONS: In patients with CRC, those with low SMD were found to have elevated risks of disease-specific and overall mortality, independent of MM or adiposity. Clinical practice should incorporate body composition measures into the evaluation of the health status of patients with CRC. Cancer 2018;124:3008-15.
Authors: Susanne Blauwhoff-Buskermolen; Kathelijn S Versteeg; Marian A E de van der Schueren; Nicole R den Braver; Johannes Berkhof; Jacqueline A E Langius; Henk M W Verheul Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: Hánah N Rier; Agnes Jager; Stefan Sleijfer; Joost van Rosmalen; Marc C J M Kock; Mark-David Levin Journal: Breast Date: 2016-10-27 Impact factor: 4.380
Authors: Colin H Richards; Campbell S D Roxburgh; Mark T MacMillan; Sanad Isswiasi; Ewen G Robertson; Graeme K Guthrie; Paul G Horgan; Donald C McMillan Journal: PLoS One Date: 2012-08-03 Impact factor: 3.240
Authors: David P J van Dijk; Maikel J A M Bakens; Mariëlle M E Coolsen; Sander S Rensen; Ronald M van Dam; Martijn J L Bours; Matty P Weijenberg; Cornelis H C Dejong; Steven W M Olde Damink Journal: J Cachexia Sarcopenia Muscle Date: 2016-10-26 Impact factor: 12.910
Authors: Iva Miljkovic; Jane A Cauley; Patty Y Wang; Kathleen F Holton; Christine G Lee; Yahtyng Sheu; Elizabeth Barrett-Connor; Andrew R Hoffman; Cora B Lewis; Eric S Orwoll; Marcia L Stefanick; Elsa S Strotmeyer; Lynn M Marshall Journal: Obesity (Silver Spring) Date: 2013-05-29 Impact factor: 5.002
Authors: Stefanie Aust; Thomas Knogler; Dietmar Pils; Eva Obermayr; Alexander Reinthaller; Lisa Zahn; Ilja Radlgruber; Marius Erik Mayerhoefer; Christoph Grimm; Stephan Polterauer Journal: PLoS One Date: 2015-10-12 Impact factor: 3.240
Authors: Harm van Baar; S Beijer; M J L Bours; M P Weijenberg; M van Zutphen; F J B van Duijnhoven; G D Slooter; J F M Pruijt; J J Dronkers; A Haringhuizen; E J Spillenaar Bilgen; B M E Hansson; J H W de Wilt; E Kampman; R M Winkels Journal: J Cancer Res Clin Oncol Date: 2018-08-17 Impact factor: 4.553
Authors: Jingjie Xiao; Bette J Caan; Elizabeth M Cespedes Feliciano; Jeffrey A Meyerhardt; Candyce H Kroenke; Vickie E Baracos; Erin Weltzien; Marilyn L Kwan; Stacey E Alexeeff; Adrienne L Castillo; Carla M Prado Journal: Am J Clin Nutr Date: 2019-03-01 Impact factor: 7.045
Authors: Robert D Boutin; Jeremy R Katz; Abhijit J Chaudhari; Jonathan G Yabes; Jonah S Hirschbein; Yves-Paul Nakache; J Anthony Seibert; Ramit Lamba; Ghaneh Fananapazir; Robert J Canter; Leon Lenchik Journal: Quant Imaging Med Surg Date: 2020-08
Authors: Isabel Molwitz; Marius Kemper; Linda Krause; Gerhard Adam; Jakob Robert Izbicki; Christoph Burdelski; Geraldine de Heer; Laura Gerdes; Jin Yamamura; Jun Li Journal: Ann Transl Med Date: 2022-09
Authors: Jingjie Xiao; Bette J Caan; Erin Weltzien; Elizabeth M Cespedes Feliciano; Candyce H Kroenke; Jeffrey A Meyerhardt; Vickie E Baracos; Marilyn L Kwan; Adrienne L Castillo; Carla M Prado Journal: J Cachexia Sarcopenia Muscle Date: 2018-04-19 Impact factor: 12.910